555 related articles for article (PubMed ID: 11745236)
1. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
[TBL] [Abstract][Full Text] [Related]
8. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
[TBL] [Abstract][Full Text] [Related]
11. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
13. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
Madajewicz S; Hentschel P; Burns P; Caruso R; Fiore J; Fried M; Malhotra H; Ostrow S; Sugarman S; Viola M
J Clin Oncol; 2000 Oct; 18(20):3553-7. PubMed ID: 11032598
[TBL] [Abstract][Full Text] [Related]
14. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
[TBL] [Abstract][Full Text] [Related]
17. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
18. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
[TBL] [Abstract][Full Text] [Related]
20. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]